2015 Annual Meeting | Management of Asymptomatic Cerebrovascular Lesions
| 01:00 PM - 01:05 PM |
Introduction
Antonio Culebras, MD, FAHA, FAAN |
|
| 01:00 PM - 05:00 PM | Abstract |
001 - 5A: Prevalence and healing rates of Duplex detected carotid plaque ulcers
Sushrut Dharmadhikari, MD |
| 01:00 PM - 05:00 PM | Abstract |
002 - Coated-platelet levels are associated with stenosis progression in patients with carotid atherosclerosis
Angelia Kirkpatrick |
| 01:00 PM - 05:00 PM | Abstract |
003 - A Population-based Study of the Incidence and Case Fatality of Intracerebral Hemorrhage of Undetermined Etiology
|
| 01:00 PM - 05:00 PM | Abstract |
004 - Accurate outcome predictions for intracerebral hemorrhage patients are more likely than inaccurate predictions to be influenced by co-morbidities not included in clinical scales
David Y. Hwang, MD, FAAN |
| 01:00 PM - 05:00 PM | Abstract |
005 - Patients Consenting to or Declining Extended Follow-up (Up to Ten Years) in the Carotid Revascularization Endarterectomy (CEA) versus Stenting (CAS) Trial (CREST)
Alice J. Sheffet, PhD |
| 01:00 PM - 05:00 PM | Abstract |
006 - Are patients with carotid stenosis receiving optimal medical therapy?
Sebastian Koch, MD |
| 01:00 PM - 05:00 PM | Abstract |
007 - Cognitive implications of revascularization in asymptomatic carotid stenosis
Chun-Jen Lin |
| 01:00 PM - 05:00 PM | Abstract |
008 - Angiographically occult micro-arteriovenous malformation as a rare cause of recurrent Intracerebral hemorrhage
Anand V. Patel, MD |
| 01:00 PM - 05:00 PM | Abstract |
009 - Exceptional aggressiveness of cerebral cavernous malformation disease associated with PDCD10 mutations.
Tania J. Rebeiz, MD |
| 01:00 PM - 05:00 PM | Abstract |
010 - Predictors of Seizure Presentation associated with Cerebral Arteriovenous Malformations in a Prospective Cohort of 1,007 Patients
Dale Ding, MD |
| 01:00 PM - 05:00 PM | Abstract |
012 - Prevalence of Asymptomatic Cerebral Aneurysm in General population and Ischemic Stroke Patient
|
| 01:00 PM - 05:00 PM | Abstract |
013 - Impact of Menopausal age on Size of Unruptured Intracranial Aneurysms and Their Outcomes With Endovascular Therapy
Sushrut Dharmadhikari, MD |
| 01:05 PM - 01:35 PM |
Uncertainties and Future Directions in Managing Asymptomatic Carotid Disease: CREST-2.
James F. Meschia, MD, FAAN |
|
| 01:35 PM - 01:40 PM |
Are Patients with Carotid Stenosis Receiving Optimal Medical Therapy?
Sebastian Koch, MD |
|
| 01:40 PM - 01:45 PM |
Cognitive Implications of Revascularization in Asymptomatic Carotid Stenosis
Chun-Jen Lin |
|
| 01:45 PM - 01:55 PM |
Audience Q&A
|
|
| 01:55 PM - 02:25 PM |
Intracranial Cavernous Malformations: Natural History, Genetics, Management, and Future Directions in Research
Michael Lawton, MD |
|
| 02:25 PM - 02:30 PM |
Angiographically Occult Micro-arteriovenous Malformation as a Rare Cause of Recurrent Intracerebral Hemorrhage
|
|
| 02:30 PM - 02:35 PM |
Exceptional Aggressiveness of Cerebral Cavernous Malformation Disease Associated with PDCD10 Mutations
Tania J. Rebeiz, MD |
|
| 02:35 PM - 02:45 PM |
Audience Q&A
|
|
| 02:45 PM - 02:55 PM |
Break
|
|
| 02:55 PM - 03:25 PM |
Unruptured Brain Arteriovenous Malformations: Management, Controversies, and Future Directions in Research. The ARUBA Experience.
J. P. Mohr, MD, FAAN |
|
| 03:25 PM - 03:30 PM |
Predictors of Seizure Presentation associated with Cerebral Arteriovenous Malformations in a Prospective Cohort of 1,007 Patients
Dale Ding, MD |
|
| 03:30 PM - 03:35 PM |
Accurate outcome predictions for intracerebral hemorrhage patients are more likely than inaccurate predictions to be influenced by co-morbidities not included in clinical scales
David Y. Hwang, MD, FAAN |
|
| 03:35 PM - 03:45 PM |
Audience Q&A
|
|
| 03:45 PM - 04:15 PM |
Unruptured Intracranial Aneurysms: Uncertainties in Management and Future Directions in Research
Robert D. Brown, Jr., MD, MPH, FAAN |
|
| 04:15 PM - 04:20 PM |
Prevalence of Asymptomatic Cerebral Aneurysm in General Population and Ischemic Stroke Patient
|
|
| 04:20 PM - 04:25 PM |
Impact of Menopausal Age on Size of Unruptured Intracranial Aneurysms and Their Outcomes with Endovascular Therapy
Sushrut Dharmadhikari, MD |
|
| 04:25 PM - 04:35 PM |
Questions and Answers
|
|
| 04:35 PM - 05:00 PM |
Guided Poster Rounds
|
| Robert D. Brown, Jr., MD, MPH, FAAN | Dr. Brown has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for Craig H Neilsen Foundation. The institution of Dr. Brown has received research support from National Institutes of Health/NINDS. Dr. Brown has received publishing royalties from a publication relating to health care. |
| J. P. Mohr, MD, FAAN | The institution of Dr. Mohr has received research support from NINDS Grant R01 NS099268 NIH-NINDS . |
| Sebastian Koch, MD | Dr. Koch has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Multiple Legal Matters. Dr. Koch has received stock or an ownership interest from Cerepeutics. Dr. Koch has received intellectual property interests from a discovery or technology relating to health care. Dr. Koch has received intellectual property interests from a discovery or technology relating to health care. |
| Antonio Culebras, MD, FAHA, FAAN | Dr. Culebras has received personal compensation in the range of $500-$4,999 for serving as an officer or member of the Board of Directors for MEDLINK NEUROLOGY. Dr. Culebras has received personal compensation in the range of $500-$4,999 for serving as an officer or member of the Board of Directors for MEDLINK NEUROLOGY. Dr. Culebras has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for MEDLINK. Dr. Culebras has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for MEDLINK. Dr. Culebras has received publishing royalties from a publication relating to health care. Dr. Culebras has received personal compensation in the range of $500-$4,999 for serving as a RESEARCH REVIEWER with DEPARTMENT OF DEFENSE. Dr. Culebras has received personal compensation in the range of $500-$4,999 for serving as a REVIEWER with DOD. |
| David Y. Hwang, MD, FAAN | The institution of Dr. Hwang has received research support from NIH. The institution of Dr. Hwang has received research support from Neurocritical Care Foundation. Dr. Hwang has received publishing royalties from a publication relating to health care. Dr. Hwang has received personal compensation in the range of $10,000-$49,999 for serving as a Associate Medical Director with New England Donor Services. |
| Sushrut Dharmadhikari, MD | Dr. Dharmadhikari has nothing to disclose. |
| Chun-Jen Lin | No disclosure on file |
| Tania J. Rebeiz, MD | Dr. Rebeiz has nothing to disclose. |
| Santoshi Billakota, MD | No disclosure on file |
| No disclosure on file | |
| Dale Ding, MD | No disclosure on file |
| James F. Meschia, MD, FAAN | The institution of Dr. Meschia has received research support from NINDS. The institution of Dr. Meschia has received research support from NINDS. |
| Michael Lawton, MD | No disclosure on file |
| Virginia J. Howard, PhD | The institution of Dr. Howard has received research support from NIH. The institution of an immediate family member of Dr. Howard has received research support from NIH. |
| Wayne M. Clark, MD | Dr. Clark has nothing to disclose. |
| Norman Ajiboye, MD, FAAN | Dr. Ajiboye has nothing to disclose. |
| Carl Langefeld | No disclosure on file |
| Jonathan Rosand, MD | Dr. Rosand has received personal compensation for serving as an employee of Massachusetts General Hospital. Dr. Rosand has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eli Lilly and Co. Dr. Rosand has received personal compensation in the range of $0-$499 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Elsevier. Dr. Rosand has received personal compensation in the range of $50,000-$99,999 for serving as an Expert Witness for National Football League. The institution of Dr. Rosand has received research support from NIH. The institution of Dr. Rosand has received research support from American Heart Association. Dr. Rosand has received personal compensation in the range of $0-$499 for serving as a Peer reviewer with National Institutes of Health. Dr. Rosand has a non-compensated relationship as a Trustee with Columbia University that is relevant to AAN interests or activities. |
| Calin I. Prodan, MD | The institution of Dr. Prodan has received research support from US Department of Veterans Affairs (Merit award CX000340). |
| Meelee Tom | No disclosure on file |
| Dileep R. Yavagal, MD, FAAN | Dr. Yavagal has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Vascular Dynamics. Dr. Yavagal has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Guidepoint. The institution of Dr. Yavagal has received personal compensation in the range of $500-$4,999 for serving as a Consultant for GLG. Dr. Yavagal has received personal compensation in the range of $0-$499 for serving as a Consultant for Medtronic. Dr. Yavagal has received personal compensation in the range of $0-$499 for serving as a Consultant for Cerenovus/Johnson & Johnson. Dr. Yavagal has received personal compensation in the range of $0-$499 for serving as a Consultant for Stryker. Dr. Yavagal has received personal compensation in the range of $0-$499 for serving as a Consultant for Poseydon. Dr. Yavagal has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Athersys. Dr. Yavagal has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Gravity Medical Technology. Dr. Yavagal has received personal compensation in the range of $0-$499 for serving on a Scientific Advisory or Data Safety Monitoring board for Poseydon. Dr. Yavagal has stock in Poseydon. Dr. Yavagal has stock in Galaxy Therapeutics. Dr. Yavagal has stock in Stentrode. Dr. Yavagal has stock in Gravity Medical. Dr. Yavagal has stock in Gravity Medical Technology. Dr. Yavagal has stock in Athersys. Dr. Yavagal has stock in Rapid Medical . Dr. Yavagal has received intellectual property interests from a discovery or technology relating to health care. Dr. Yavagal has received personal compensation in the range of $5,000-$9,999 for serving as a Medicolegal Expert with Royal Carribean Cruise Line. Dr. Yavagal has received personal compensation in the range of $5,000-$9,999 for serving as a Medicolegal Consultant with Carnival Cruise Line. |
| Seemant Chaturvedi, MD, FAHA, FAAN | Dr. Chaturvedi has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Astra Zeneca. Dr. Chaturvedi has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for University of Calgary. Dr. Chaturvedi has received personal compensation in the range of $10,000-$49,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for American Heart Association. Dr. Chaturvedi has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Ramar & Paradiso. Dr. Chaturvedi has received personal compensation in the range of $10,000-$49,999 for serving as an Expert Witness for Cole, Scott, Kissane. The institution of Dr. Chaturvedi has received research support from NINDS. |
| Kevin N. Sheth, MD, FAAN | Dr. Sheth has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Ceribell. Dr. Sheth has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Zoll. Dr. Sheth has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for NControl. Dr. Sheth has received stock or an ownership interest from Astrocyte. Dr. Sheth has received stock or an ownership interest from Alva. The institution of Dr. Sheth has received research support from Biogen. The institution of Dr. Sheth has received research support from Novartis. The institution of Dr. Sheth has received research support from Bard. The institution of Dr. Sheth has received research support from Hyperfine. Dr. Sheth has received intellectual property interests from a discovery or technology relating to health care. |
| Thomas G. Brott, MD, FAAN | Dr. Brott has nothing to disclose. |
| Alice J. Sheffet, PhD | No disclosure on file |
| Ariane E. Mackey, MD | No disclosure on file |
| Mark S. Quigg, MD | Dr. Quigg has received personal compensation for serving as an employee of Natus. Dr. Quigg has received personal compensation for serving as an employee of Neurocrine. Dr. Quigg has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Cerebral Therapeutics. Dr. Quigg has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Cerebral Therapeutics. Dr. Quigg has received personal compensation in the range of $500-$4,999 for serving as an Expert Witness for Finnigen and Harrison. Dr. Quigg has received research support from NIH. Dr. Quigg has received publishing royalties from a publication relating to health care. |
| Hamza I. Maqsood, MD | Dr. Qureshi has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for AstraZeneca. |
| Jose G. Romano, MD, FAAN | Dr. Romano has stock in Vycor Medical/NovaVision. The institution of Dr. Romano has received research support from NIH/NINDS. The institution of Dr. Romano has received research support from NIH/NHLBI. |
| Pei-Ning Wang, MD | Dr. Wang has nothing to disclose. |
| Issam Awad, MD | No disclosure on file |
| Muhammad F. Suri, MD | Dr. Suri has nothing to disclose. |
| Steven J. Kittner, MD, MPH | The institution of Dr. Kittner has received research support from NINDS. |
| Jessica McFarlin, MD | Dr. McFarlin has received personal compensation in the range of $500-$4,999 for serving as a Volunteer Faculty with Vital Talk. |
| Robert Starke | No disclosure on file |
| Kunakorn Atchaneeyasakul, MD | No disclosure on file |
| Ajit Puri | No disclosure on file |
| Ajay M. Tunguturi, MD | Dr. Tunguturi has nothing to disclose. |
| Anand V. Patel, MD | Dr. Patel has nothing to disclose. |
| Andrea Vincent | Andrea Vincent has received personal compensation for serving as an employee of Vista LifeSciences. The institution of Andrea Vincent has received research support from Medical Technology Enterprise Consortium (MTEC). |
| Nada El Husseini, MD, FAAN | The institution of Dr. El Husseini has received research support from the DISCOVERY trial funded by the National Institute of Neurological Disorders and Stroke (NINDS)and the National Institute on Aging (NIA) (U19NS115388).- subcontract from MGH. |
| Majaz Moonis, MD, FAHA, FAAN | Dr. Moonis has nothing to disclose. |
| Angelia Kirkpatrick | Angelia Kirkpatrick has nothing to disclose. |
| Jennifer Osborne, NP | No disclosure on file |
| I-Hui Lee, MD, PhD | Dr. Lee has nothing to disclose. |
| Ahmed A. Malik, MD | No disclosure on file |
| George Dale | George Dale has nothing to disclose. |
| Michael L. James, MD | Dr. James has nothing to disclose. |
| Daniel Woo, MD, FAAN | The institution of Dr. Woo has received research support from NIH. |
| Michael D. Hill, MD | Dr. Hill has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Boehringer Ingelheim. Dr. Hill has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sun Pharma. Dr. Hill has received stock or an ownership interest from Circle Neurovascular. |
| Mushtaq H. Qureshi, MD | No disclosure on file |
| Abdul Ghani Mikati, MD | No disclosure on file |
| Nelly Campo | No disclosure on file |
| Amy Akers, MD | No disclosure on file |
| Jenifer Voeks | Jenifer Voeks has nothing to disclose. |
| Susan E. Hughes | No disclosure on file |
| Jong Yun Lee | No disclosure on file |
| Sang Won Han | No disclosure on file |